A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia
RESPONSE TO CYTARABINE, DAUNORUBICIN AND ETOPOSIDE (ADE) AT FIRST RELASPE IN CHILDHOOD AML
Sponsor: All India Institute of Medical Sciences
A PHASE2 clinical study on Acute Myeloid Leukemia, in Relapse, this trial is ongoing. The trial is conducted by All India Institute of Medical Sciences and has accumulated 7 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Jul 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- All India Institute of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.